Intraoperative Dexmedetomidine Use, MMP-8, and Postoperative Delirium After Cardiac Surgery With Cardiopulmonary Bypass
Key facts
- Who runs it
- Shusheng Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 5,688 people enrolled
- Started
- 1 Apr 2023
- Ended
- 15 Oct 2024
- Type of study
- Observational, 4 groups
- Treatments tested
- Dexmedetomidine
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)
- For the retrospective cohort, eligible patients undergoing cardiac surgery with CPB at the three participating campuses of Tongji Hospital between January 2015 and December 2022
- For the prospective biomarker cohort, eligible participants enrolled between April 2023 and September 2024 with archived plasma samples collected preoperatively, at the end of surgery, and 24 h postoperatively, together with linked clinical data
Who cannot take part
- Emergency surgery
- Conditions precluding dexmedetomidine use, including second- or third-degree atrioventricular block without a pacemaker, uncontrolled hypotension, acute cerebrovascular disease, or known hypersensitivity to dexmedetomidine
- Severe neurological or psychiatric disorders, including a history of treatment for severe mental illness
- Inability to communicate effectively because of severe hearing, visual, or speech impairments
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational study evaluated the association between intraoperative dexmedetomidine use and postoperative delirium (POD) in adults undergoing cardiac surgery with cardiopulmonary bypass (CPB). The study included two linked clinical components. First, routinely collected clinical data from patients undergoing cardiac surgery with CPB at three campuses of Tongji Hospital between January 2015 and December 2022 were analyzed to evaluate the dexmedetomidine-POD association. Second, perioperative plasma samples and clinical data from a prospective observational cohort enrolled between April 2023 and September 2024 were used to characterize perioperative matrix metalloproteinase-8 (MMP-8) dynamics and their associations with intraoperative dexmedetomidine use and POD. Dexmedetomidine administration was determined by the attending anesthesiologist according to clinical judgment and routine anesthetic practice and was not assigned by the study protocol.
The 4 groups in the trial
- Retrospective Cohort - Dexmedetomidine Exposed
Patients in the retrospective multicampus cohort who underwent cardiac surgery with cardiopulmonary bypass between January 2015 and December 2022 and received intraoperative dexmedetomidine by continuous intravenous infusion as part of routine anesthetic care. Dexmedetomidine administration was determined by the attending anesthesiologist according to clinical judgment and was not assigned by the study protocol.
Treatment: Dexmedetomidine
- Retrospective Cohort - No Dexmedetomidine Exposure
Patients in the retrospective multicampus cohort who underwent cardiac surgery with cardiopulmonary bypass between January 2015 and December 2022 and did not receive intraoperative dexmedetomidine.
- Prospective Cohort - Dexmedetomidine Exposed
Participants in the previously established prospective observational cohort who underwent cardiac surgery with cardiopulmonary bypass between April 2023 and September 2024 and received intraoperative dexmedetomidine as part of routine anesthetic care. Dexmedetomidine use was determined by the treating anesthesiologist and was not influenced by the study investigators. Archived perioperative plasma samples from these participants were used for the present MMP-8 analyses.
Treatment: Dexmedetomidine
- Prospective Cohort - No Dexmedetomidine Exposure
Participants in the previously established prospective observational cohort who underwent cardiac surgery with cardiopulmonary bypass between April 2023 and September 2024 and did not receive intraoperative dexmedetomidine. Archived perioperative plasma samples from these participants were used for the present MMP-8 analyses.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Association of Intraoperative Dexmedetomidine Use and Perioperative Plasma MMP-8 Dynamics With Postoperative Delirium in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
- Record updated
- 9 September 2026